Unfortunately, another negative study of a drug being accretive to CHOP regimen in T-cell NHL. Newer drugs and concepts hopefully will move the needle in this decade.
Interesting and encouraging development in this setting. The science and applicability of this drug in the scenario of no/low HER-2 expression will be thought-provoking. Interstitial pneumonitis is a concern.
Incredible development for a small population of patients with uveal melanoma but nonetheless a new standard of care. Initial infusions may be complex in terms of close monitoring, as inpatient, till more experience is acquired in community oncology practices.
Another win for combined target-IO Rx with meaningful OS difference and reasonable/expected tolerability.
A single-group, phase 1–2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.
PFS difference is small. But argument can be made for a younger patient who desires aggressive therapy and toxicities have been manageable.
Interesting and common scenario in clinic. Self-reported symptoms do exist but delaying disease-progression may have salutary benefits in the long haul insofar as using dual androgen-deprivation therapy.
Role adjuvant chemotherapy in this setting will change significantly with incorporation of MRD evaluation post-surgery with prospective validation.
Benefit of locoregional control seems limited probably to situations in which surgery could clearly help recurrent breast inflammatory/infectious issues. This study is helpful to quote to patients who are anxious about not having breast surgery accomplished in this setting.
Many of us have used platinum/paclitaxel in this setting but this study helps to corroborate the clinical practice.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
